Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.50 |
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA12 | O43570 | 9/20 | 0.50 |
| ▸ | CA9 | Q16790 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403674 | 0.88 | CA1 (0.45) | CA1CA2CA12CA9MAPT | |
| SCHEMBL3406389 | 0.87 | CA1 (0.44) | CA1CA2CA12CA9MAPT | |
| SCHEMBL3406370 | 0.86 | MAPT (0.37) | CA1CA2CA12CA9MAPT | |
| SCHEMBL3405074 | 0.84 | CA1 (0.42) | CA1CA2CA12CA9MAPT | |
| SCHEMBL3410435 | 0.84 | NPC1 (0.42) | CA2CA12CA9MAPTKMT2A | |
| SCHEMBL3405799 | 0.83 | MAPT (0.38) | MAPTKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3407910 | 0.82 | MTOR (0.41) | MAPTKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3408068 | 0.82 | LMNA (0.37) | MAPTKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3405694 | 0.81 | CA2 (0.45) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL3404471 | 0.80 | CA1 (0.41) | CA1CA2CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | CA1 834/4885CA2 297/4885CA12 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.